ViVita Technologies Revenue and Competitors

BIOMATERIALS ENABLING REGENERATIVE MEDICINE Imagine if there was no need for an organ transplant waiting list or anti-rejection medication because we could use robust and long-lasting organ and tissue replacements from animals without fear of immune rejection. ViVita addresses this need using its patented SPEAR Process to prepare human immune-compatible animal tissues that retain important structural and bioactive features needed for successful transplantation and performance over a patient’s lifetime. ViVita’s initial product—BARE Patch—will enable a new generation of regenerative replacement heart valves that avoids the limited longevity and need for repeat replacement surgeries associated with current valve bioprostheses.